Late toxicity printout — GYN

Cited monitoring paradigm

Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, nausea, and vaginal or vulvar field irritation. Late: radiation proctitis and cystitis, incontinence, fistula, menopause symptoms, fertility effects, low estrogen, osteoporosis, lymphedema, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: pelvic bleeding, pain, or leakage after RT; regular cervical screening may be named; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not a CA-125, HPV-dose, or ASCCP engine.

Not a fourth printout section. Cadences stay placeholders. Named tests are not encoded.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

ACS long-term and follow-up-care lists, named not encoded. Not a fourth printout section.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

ACS follow-up-care named contents. Not a fourth printout section.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS follow-up-care named steps. Not a fourth printout section.

Acute toxicities

During or shortly after RT. ACS early side effects.

• Fatigue — ACS names fatigue as a common early RT side effect.ACS-radiation-body
• Radiation dermatitis — ACS names pelvic-field skin irritation.ACS-radiation-body
• Short-term rectal and bladder problems — ACS names diarrhea, bowel urgency, painful urination, and urinary urgency after pelvis RT.ACS-radiation-body
• Nausea or cramping — ACS names nausea, vomiting, and belly cramping after pelvis RT.ACS-radiation-body
• Vaginal or vulvar field irritation — ACS pelvis page names nearby-organ irritation. Vulva stays on the ACS living-as pointer.ACS-radiation-body

Late toxicities

Months to years after RT. ACS delayed effects.

ACS long-term late names: Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT

• Radiation proctitis and cystitis — ACS names later rectal or bladder lining damage.ACS-radiation-body
• Urinary or bowel incontinence — ACS names later leakage after pelvic RT.ACS-radiation-body
• Fistula — ACS names a rare opening between pelvic organs, such as vagina and bladder. No invented trial percent.ACS-radiation-body
• Menopause symptoms after pelvic RT — ACS names stopped periods and menopause symptoms after pelvic RT in some people. Not a hormone engine.ACS-radiation-body
• Fertility — ACS names fertility effects after pelvic RT. Not a fertility-preservation engine.ACS-radiation-body
• Second-cancer awareness — ACS cervix, vulva, uterus, and ovary after-treatment pages name later cancers. Vulva says additional testing in women without symptoms is not recommended. Named later-cancer sites are not encoded. Not an HPV-dose, ASCCP, or CA-125 engine.ACS-cervix-follow
• Low estrogen after pelvic treatment — ACS long-term page names low estrogen after oophorectomy, pelvic radiation, or hormone-blocking medicines, including hot flashes, bone loss, vaginal dryness, and pain with sexual activity. Not a hormone engine.ACS-long-term-effects
• Osteoporosis after hormone-affecting treatment — ACS long-term page names osteopenia and osteoporosis after treatments that affect hormones. Named only on fields that already name hormone-affecting treatment. Not a DXA-interval engine.ACS-long-term-effects
• Low estrogen or testosterone after hormone-affecting treatment — ACS long-term page names low estrogen or testosterone after ovary or testis surgery, pelvic or prostate radiation, hormone-blocking medicines, chemo, or steroids. Highest named risks are breast, ovarian, testicular, and prostate cancer. Named only on fields that already name hormone-affecting treatment. Not a testosterone or hormone-lab engine.ACS-long-term-effects
• Osteonecrosis of the jaw after bisphosphonates — ACS long-term page names osteonecrosis of the jaw after radiation to the jawbone or medicines used to prevent bone loss, called bisphosphonates. Named only on fields that already name osteoporosis after hormone-affecting treatment. Not a dental-calendar engine.ACS-long-term-effects
• Vision change after hormone therapy — ACS long-term page names vision change, cataracts, or glaucoma after some hormone therapies, as well as some chemo, targeted therapies, or immunotherapies. Named only on fields that already name hormone-affecting treatment and do not already carry a head-or-eye RT vision row. Not an eye-screening engine.ACS-long-term-effects
• Lymphedema after pelvic-node surgery or RT — ACS long-term page names lymphedema after lymph-node surgery or radiation. Not a stage engine.ACS-long-term-effects
• Cancer-related fatigue that lasts — ACS long-term page names cancer-related fatigue as the most common long-term effect, lasting months or years and not always improving with rest. Sleep problems are also named and may have more than one cause.ACS-long-term-effects
• Joint or muscle pain after some treatments — ACS long-term page names joint or muscle pain after chemo, steroids, or hormone therapy. Symptoms may improve over time. People who are not physically active may have a higher risk. Not a rehab-interval engine.ACS-long-term-effects
• Mental health and distress after treatment — ACS long-term page names anxiety, depression, post-traumatic stress, loneliness, and fear of recurrence among common mental-health effects after cancer treatment. Not a mental-health screening engine.ACS-long-term-effects
• Second cancers after radiation or chemo — ACS adult second-cancers hub says a second cancer is a new unrelated cancer, not a recurrence. Radiation is linked to later AML, CML, ALL, or MDS, and to solid tumors that more often show up 10 years or more later, including breast, lung, thyroid, or bone and soft-tissue sarcomas. Chemo is linked most often to MDS and AML; ALL is also named. Chemo is named as a greater leukemia risk factor than radiation. Those names are not encoded. Complementary to the cervix, vulva, uterus, and ovary after-treatment pages. GTD stays out of domain. Not a CA-125, HPV-dose, or ASCCP engine.ACS-second-cancers-adults
• Follow-up care plan after treatment — ACS follow-up-care page, developed with ASCO review, names a cancer treatment summary and a survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical, breast, colorectal, or lung screening may be named. Those plans and screens are not encoded. Regular cervical screening may be named. GTD stays out of domain. Not a CA-125, HPV-dose, or ASCCP engine.ACS-follow-up-care

Named conditions to monitor

Red flags and suggested follow-up cadence placeholders. Not a personal calendar.

• Pelvic bleeding, pain, or leakage after RT

  Pelvic bleeding, pain, or leakage after RT — ACS names later hematuria, rectal bleeding, incontinence, or fistula symptoms as reasons to contact the care team. Visit-directed pelvic-toxicity placeholder — not encoded. Not an ASCCP management engine.

  ACS-radiation-body

• Menopause symptoms

  Menopause symptoms — ACS says to report stopped periods or other menopause symptoms after pelvic RT. Symptom-directed placeholder — not encoded.

  ACS-radiation-body

• Cervix first-row toxicity

  Cervix first-row toxicity — Cervix-treatment toxicity stays empty on purpose on the first pointer. Empty on purpose. Complementary ACS living-as months are not encoded.

  ACS-cervix-follow

• Bone density after hormone-affecting treatment

  Bone density after hormone-affecting treatment — ACS long-term page names osteopenia and osteoporosis after treatments that affect hormones. Bone-health placeholder — not encoded. Not a DXA-interval or CA-125 engine.

  ACS-long-term-effects

• Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment

  Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment — ACS long-term page names hot flashes, cognitive changes, bone loss, changes in sex drive, and weight gain after low estrogen or testosterone. Named effects are not encoded. Not a testosterone, hormone-lab, or CA-125 engine.

  ACS-long-term-effects

• Dental check before bisphosphonates

  Dental check before bisphosphonates — ACS long-term page names a dental check before jaw RT or bisphosphonates so tooth problems can be treated first. Named dental-check-before-start is not encoded. The named 6-month dental interval stays on the head-and-neck printout. Not a dental-calendar engine.

  ACS-long-term-effects

• Vision change after hormone therapy

  Vision change after hormone therapy — ACS long-term page says to ask the care team about seeing an eye doctor after vision change from cancer treatment. Referral placeholder — not encoded. Not an eye-screening engine.

  ACS-long-term-effects

• Cancer-related fatigue or sleep problems that last

  Cancer-related fatigue or sleep problems that last — ACS long-term page names cancer-related fatigue as the most common long-term effect, plus sleep problems after treatment. Named months-or-years window is not encoded. Placeholder only — not a fatigue-score engine.

  ACS-long-term-effects

• Joint or muscle pain after chemo, steroids, or hormone therapy

  Joint or muscle pain after chemo, steroids, or hormone therapy — ACS long-term page names joint or muscle pain after those treatments and says symptoms may improve over time. Named activity and rehab steps are not encoded. Placeholder only — not a rehab-interval engine.

  ACS-long-term-effects

• Anxiety, depression, or fear of recurrence after treatment

  Anxiety, depression, or fear of recurrence after treatment — ACS long-term page names those as common types of mental distress among cancer survivors and says very worried, depressed, or angry feelings can affect daily life. Named support steps are not encoded. Placeholder only — not a mental-health screening engine.

  ACS-long-term-effects

• Second-cancer awareness after radiation or chemo

  Second-cancer awareness after radiation or chemo — ACS adult second-cancers hub names later MDS or leukemia after some chemo or radiation, and later solid tumors after radiation. Complementary to the cervix, vulva, uterus, and ovary after-treatment pages. GTD stays out of domain. Not a CA-125, HPV-dose, or ASCCP engine. Named several-year and 10-year windows are not encoded. Symptom-directed placeholder — not a second-primary screening engine.

  ACS-second-cancers-adults

• Ask which late-effect tests belong on the follow-up plan

  Ask which late-effect tests belong on the follow-up plan — ACS follow-up-care page names special tests after some treatments. Ask which tests belong on the plan after pelvis treatment. Regular cervical screening may be named. Those named tests are not encoded. GTD stays out of domain. Not a CA-125, HPV-dose, or ASCCP engine. Named yearly and age-30 intervals are not encoded. Placeholder only — not a second-primary screening engine.

  ACS-follow-up-care